Strategy Asset Managers’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-386
| Closed | -$224K | – | 287 |
|
|
2025
Q4 | $224K | Buy |
+386
| New | +$218K | 0.04% | 242 |
|
|
2025
Q3 | – | Sell |
-640
| Closed | -$259K | – | 273 |
|
|
2025
Q2 | $259K | Sell |
640
-1,602
| -71% | -$670K | 0.05% | 209 |
|
|
2025
Q1 | $1.12M | Buy |
2,242
+133
| +6% | +$72K | 0.23% | 78 |
|
|
2024
Q4 | $1.1M | Sell |
2,109
-86
| -4% | -$47.3K | 0.21% | 79 |
|
|
2024
Q3 | $1.36M | Buy |
2,195
+524
| +31% | +$310K | 0.26% | 71 |
|
|
2024
Q2 | $872K | Sell |
1,671
-454
| -21% | -$260K | 0.19% | 88 |
|
|
2024
Q1 | $1.24M | Buy |
2,125
+241
| +13% | +$135K | 0.26% | 69 |
|
|
2023
Q4 | $1M | Buy |
1,884
+2
| +0.1% | +$968 | 0.24% | 74 |
|
|
2023
Q3 | $953K | Buy |
1,882
+211
| +13% | +$112K | 0.25% | 75 |
|
|
2023
Q2 | $872K | Buy |
1,671
+77
| +5% | +$41.6K | 0.19% | 88 |
|
|
2023
Q1 | $919K | Buy |
1,594
+6
| +0.4% | +$3.38K | 0.22% | 80 |
|
|
2022
Q4 | $875K | Buy |
1,588
+7
| +0.4% | +$3.71K | 0.22% | 84 |
|
|
2022
Q3 | $802K | Buy |
1,581
+470
| +42% | +$263K | 0.22% | 85 |
|
|
2022
Q2 | $604K | Buy |
1,111
+79
| +8% | +$43.5K | 0.19% | 98 |
|
|
2022
Q1 | $610K | Sell |
1,032
-126
| -11% | -$72.4K | 0.13% | 134 |
|
|
2021
Q4 | $773K | Buy |
1,158
+49
| +4% | +$30.6K | 0.2% | 95 |
|
|
2021
Q3 | $634K | Sell |
1,109
-2,397
| -68% | -$1.32M | 0.14% | 135 |
|
|
2021
Q2 | $1.77M | Sell |
3,506
-31
| -0.9% | -$14.6K | 0.37% | 60 |
|
|
2021
Q1 | $1.61M | Buy |
3,537
+112
| +3% | +$53.5K | 0.37% | 55 |
|
|
2020
Q4 | $1.6M | Sell |
3,425
-308
| -8% | -$144K | 0.38% | 53 |
|
|
2020
Q3 | $1.65M | Buy |
3,733
+38
| +1% | +$15.7K | 0.43% | 52 |
|
|
2020
Q2 | $1.34M | Buy |
3,695
+127
| +4% | +$42.6K | 0.36% | 54 |
|
|
2020
Q1 | $1.01M | Sell |
3,568
-169
| -5% | -$53.3K | 0.33% | 60 |
|
|
2019
Q4 | $1.21M | Buy |
3,737
+488
| +15% | +$148K | 0.3% | 56 |
|
|
2019
Q3 | $946K | Sell |
3,249
-66
| -2% | -$18.9K | 0.28% | 52 |
|
|
2019
Q2 | $974K | Sell |
3,315
-8,431
| -72% | -$2.32M | 0.28% | 54 |
|
|
2019
Q1 | $3.21M | Sell |
11,746
-1,883
| -14% | -$469K | 0.72% | 35 |
|
|
2018
Q4 | $3.05M | Sell |
13,629
-387
| -3% | -$90.8K | 0.74% | 37 |
|
|
2018
Q3 | $3.42M | Buy |
+14,016
| New | +$3.22M | 0.7% | 38 |
|
|
2014
Q3 | – | Sell |
-27,203
| Closed | -$3.21M | – | 146 |
|
|
2014
Q2 | $3.21M | Sell |
27,203
-389
| -1% | -$45.8K | 0.68% | 46 |
|
|
2014
Q1 | $3.32M | Sell |
27,592
-866
| -3% | -$103K | 0.71% | 41 |
|
|
2013
Q4 | $3.17M | Sell |
28,458
-469
| -2% | -$46.6K | 0.69% | 47 |
|
|
2013
Q3 | $2.67M | Buy |
+28,927
| New | +$2.62M | 0.63% | 61 |
|
Other funds holding TMO
VCM
Strategy Asset Managers's TMO Position: Q1 2026 in Review
Strategy Asset Managers sold out of Thermo Fisher Scientific (TMO) in Q1 2026, closing a stake of 386 shares — an estimated $224K sold.
Strategy Asset Managers first reported a position in TMO in Q3 2013 and held it in 33 quarters. The position peaked at $3.42M in Q3 2018. 2,590 funds tracked by Wall St. Rank hold TMO as of Q1 2026.
- Strategy Asset Managers reported no remaining Thermo Fisher Scientific position as of Q1 2026 after selling out during the quarter.
- Strategy Asset Managers sold 386 Thermo Fisher Scientific shares in Q1 2026, an estimated $224K.
- Strategy Asset Managers first reported a position in Thermo Fisher Scientific in Q3 2013 and held it in 33 quarters.
- Strategy Asset Managers's Thermo Fisher Scientific position peaked at $3.42M in Q3 2018.
- 2,590 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.
Based on Strategy Asset Managers's 13F filing for Q1 2026, filed 12 May 2026.